Molecular competition between plasminogen activator inhibitors type -1 and -2 for urokinase: Implications for cellular proteolysis and adhesion in cancer

Cancer Letters

Volumn 303, Issue 2, 2011, Pages 118-127

  Lobov, Sergei ^a,b   Ranson, Marie ^a  

^a UNIVERSITY OF WOLLONGONG   (Australia)

^b AUSTRALIAN NATIONAL UNIVERSITY   (Australia)

Author keywords

Adhesion; Migration; PAI 1 SERPINE1; PAI 2 SERPINB2; Urokinase

Indexed keywords

PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; SERINE PROTEINASE INHIBITOR; UROKINASE; VITRONECTIN;

ARTICLE; CELL ADHESION; CELL MIGRATION; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; TISSUE LEVEL; TUMOR MICROENVIRONMENT;

CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CHEMOTAXIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; HUMANS; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 2; SERPINS; TIME FACTORS; TUMOR MICROENVIRONMENT; U937 CELLS; UROKINASE-TYPE PLASMINOGEN ACTIVATOR; VITRONECTIN;

EID: 79952041524     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2011.01.018     Document Type: Article

References (50)

1. Blasi F., Sidenius N. The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett. 2009, 584:1923-1930.
2. Kjoller L. The urokinase plasminogen activator receptor in the regulation of the actin cytoskeleton and cell motility. Biol. Chem. 2002, 383:5-19.
3. Ranson M., Andronicos N.M. Plasminogen binding and cancer: promises and pitfalls. Front Biosci. 2003, 8:s294-s304.
4. Friedl P., Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat. Rev. Cancer 2003, 3:362-374.
5. Joyce J.A., Pollard J.W. Microenvironmental regulation of metastasis. Nat. Rev. Cancer 2009, 9:239-252.
6. Dano K., Behrendt N., Hoyer-Hansen G., Johnsen M., Lund L.R., Ploug M., Romer J. Plasminogen activation and cancer. Thromb. Haemost. 2005, 93:676-681.
7. Ellis V., Wun T.C., Behrendt N., Ronne E., Dano K. Inhibition of receptor-bound urokinase by plasminogen-activator inhibitors. J. Biol. Chem. 1990, 265:9904-9908.
8. Croucher D.R., Saunders D.N., Stillfried G.E., Ranson M. A structural basis for differential cell signalling by PAI-1 and PAI-2 in breast cancer cells. Biochem. J. 2007, 408:203-210.
9. Croucher D., Saunders D.N., Ranson M. The urokinase/PAI-2 complex - a new high affinity ligand for the endocytosis receptor low density lipoprotein receptor-related protein. J. Biol. Chem. 2006, 281:10206-10213.
10. Strickland D.K., Ranganathan S. Diverse role of LDL receptor-related protein in the clearance of proteases and in signaling. J. Thromb. Haemost. 2003, 1:1663-1670.
11. Croucher D.R., Saunders D.N., Lobov S., Ranson M. Revisiting the biological roles of PAI2 (SERPINB2) in cancer. Nat. Rev. Cancer 2008, 8:535-545.
12. Yuan C., Huang M. Does the urokinase receptor exist in a latent form?. Cell Mol. Life Sci. 2007, 64:1033-1037.
13. Gardsvoll H., Ploug M. Mapping of the vitronectin-binding site on the urokinase receptor: involvement of a coherent receptor interface consisting of residues from both domain I and the flanking interdomain linker region. J. Biol. Chem. 2007, 282:13561-13572.
14. Madsen C.D., Ferraris G.M., Andolfo A., Cunningham O., Sidenius N. uPAR-induced cell adhesion and migration: vitronectin provides the key. J. Cell Biol. 2007, 177:927-939.
15. Hillig T., Engelholm L.H., Ingvarsen S., Madsen D.H., Gardsvoll H., Larsen J.K., Ploug M., Dano K., Kjoller L., Behrendt N. A composite role of vitronectin and urokinase in the modulation of cell morphology upon expression of the urokinase receptor. J. Biol. Chem. 2008, 283:15217-15223.
16. Kjoller L., Kanse S.M., Kirkegaard T., Rodenburg K.W., Ronne E., Goodman S.L., Preissner K.T., Ossowski L., Andreasen P.A. Plasminogen activator inhibitor-1 represses integrin- and vitronectin-mediated cell migration independently of its function as an inhibitor of plasminogen activation. Exp. Cell Res. 1997, 232:420-429.
17. Stefansson S., Lawrence D.A. Old dogs and new tricks: proteases, inhibitors, and cell migration. Sci. STKE 2003, 2003:pe24.
18. Czekay R.P., Aertgeerts K., Curriden S.A., Loskutoff D.J. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J. Cell Biol. 2003, 160:781-791.
19. Sten-Linder M., Seddighzadeh M., Engel G., Rutqvist L.E., Linder S., Skoog L., Wima B. Prognostic importance of the uPa/PAI-1 complex in breast cancer. Anticancer Res. 2001, 21:2861-2865.
20. Stutchbury T.K., Al-Ejeh F., Stillfried G.E., Croucher D.R., Andrews J., Irving D., Links M., Ranson M. Preclinical evaluation of Bi-213-labeled plasminogen activator inhibitor type 2 in an orthotopic murine xenogenic model of human breast carcinoma. Mol. Cancer Therap. 2007, 6:203-212.
21. Hang M.T.N., Ranson M., Saunders D.N., Liang X.M., Bunn C.L., Baker M.S. Pharmacokinetics of recombinant human plasminogen activator inhibitor type 2 (PAI-2) in control and tumour xenograft bearing mice. Fibrinolysis 1998, 12:145-154.
22. Cochran B.J., Gunawardhana L.P., Vine K.L., Lee J.A., Lobov S., Ranson M. The CD-loop of PAI-2 (SERPINB2) is redundant in the targeting, inhibition and clearance of cell surface uPA activity. BMC Biotechnol. 2009, 9:43.
23. Berkenpas M.B., Lawrence D.A., Ginsburg D. Molecular evolution of plasminogen activator inhibitor-1 functional stability. EMBO J. 1995, 14:2969-2977.
24. Di Giusto D.A., Sutherland A.P., Jankova L., Harrop S.J., Curmi P.M., King G.C. Plasminogen activator inhibitor-2 is highly tolerant to P8 residue substitution - implications for serpin mechanistic model and prediction of nsSNP activities. J. Mol. Biol. 2005, 353:1069-1080.
25. Al-Ejeh F., Croucher D., Ranson M. Kinetic analysis of plasminogen activator inhibitor type-2: urokinase complex formation and subsequent internalisation by carcinoma cell lines. Exp. Cell Res. 2004, 297:259-271.
26. Lobov S., Croucher D.R., Saunders D.N., Ranson M. Plasminogen activator inhibitor type 2 inhibits cell surface associated tissue plasminogen activator in vitro: potential receptor interactions. Thromb. Haemost. 2008, 100:319-329.
27. Waltz D.A., Sailor L.Z., Chapman H.A. The CD-loop of PAI-2 (SERPINB2) is redundant in the targeting, inhibition and clearance of cell surface uPA activity. J. Clin. Invest. 1993, 91:1541-1552.
28. Picone R., Kajtaniak E.L., Nielsen L.S., Behrendt N., Mastronicola M.R., Cubellis M.V., Stoppelli M.P., Pedersen S., Dano K., Blasi F. Regulation of urokinase receptors in monocytelike U937 cells by phorbol ester phorbol myristate acetate. J. Cell Biol. 1989, 108:693-702.
29. Ranson M., Andronicos N.M., O'Mullane M.J., Baker M.S. Increased plasminogen binding is associated with metastatic breast cancer cells: differential expression of plasminogen binding proteins. Br. J. Cancer 1998, 77:1586-1597.
30. Schvartz I., Seger D., Shaltiel S. Vitronectin. Int. J. Biochem. Cell Biol. 1999, 31:539-544.
31. Gutova M., Najbauer J., Frank R.T., Kendall S.E., Gevorgyan A., Metz M.Z., Guevorkian M., Edmiston M., Zhao D., Glackin C.A., Kim S.U., Aboody K.S. Urokinase plasminogen activator and urokinase plasminogen activator receptor mediate human stem cell tropism to malignant solid tumors. Stem Cells 2008, 26:1406-1413.
32. Ports M.O., Nagle R.B., Pond G.D., Cress A.E. Extracellular engagement of alpha6 integrin inhibited urokinase-type plasminogen activator-mediated cleavage and delayed human prostate bone metastasis. Cancer Res. 2009, 69:5007-5014.
33. Lijnen H.R. Pleiotropic functions of plasminogen activator inhibitor-1. J. Thromb. Haemost. 2005, 3:35-45.
34. Stefansson S., McMahon G.A., Petitclerc E., Lawrence D.A. Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr. Pharm. Des. 2003, 9:1545-1564.
35. Astedt B., Lindoff C., Lecander I. Significance of the plasminogen activator inhibitor of placental type (PAI-2) in pregnancy. Semin. Thromb. Hemost. 1998, 24:431-435.
36. Brown J.M., Watanabe K., Cohen R.L., Chambers D.A. Molecular characterization of plasminogen activators in human gingival crevicular fluid. Arch. Oral Biol. 1995, 40:839-845.
37. Kinnby B. The plasminogen activating system in periodontal health and disease. Biol. Chem. 2002, 383:85-92.
38. Madsen C.D., Sidenius N. The interaction between urokinase receptor and vitronectin in cell adhesion and signalling. Eur. J. Cell Biol. 2008, 87:617-629.
39. Waltz D.A., Chapman H.A. Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J. Biol. Chem. 1994, 269:14746-14750.
40. Chazaud B., Ricoux R., Christov C., Plonquet A., Gherardi R.K., Barlovatz-Meimon G. Promigratory effect of plasminogen activator inhibitor-1 on invasive breast cancer cell populations. Am. J. Pathol. 2002, 160:237-246.
41. Czekay R.P., Loskutoff D.J. Unexpected role of plasminogen activator inhibitor 1 in cell adhesion and detachment. Exp. Biol. Med. (Maywood) 2004, 229:1090-1096.
42. Deng G., Curriden S.A., Hu G., Czekay R.P., Loskutoff D.J. Plasminogen activator inhibitor-1 regulates cell adhesion by binding to the somatomedin B domain of vitronectin. J. Cell Physiol. 2001, 189:23-33.
43. Planus E., Barlovatz-Meimon G., Rogers R.A., Bonavaud S., Ingber D.E., Wang N. Binding of urokinase to plasminogen activator inhibitor type-1 mediates cell adhesion and spreading. J. Cell Sci. 1997, 110:1091-1098.
44. Stefansson S., Su E.J., Ishigami S., Cale J.M., Gao Y., Gorlatova N., Lawrence D.A. The contributions of integrin affinity and integrin-cytoskeletal engagement in endothelial and smooth muscle cell adhesion to vitronectin. J. Biol. Chem. 2007, 282:15679-15689.
45. Kamikubo Y., Neels J.G., Degryse B. Vitronectin inhibits plasminogen activator inhibitor-1-induced signalling and chemotaxis by blocking plasminogen activator inhibitor-1 binding to the low-density lipoprotein receptor-related protein. Int. J. Biochem. Cell Biol. 2009, 41:578-585.
46. Stefansson S., Lawrence D.A. The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectin. Nature 1996, 383:441-443.
47. D.R. Croucher, M. Ranson, D.N. Saunders, SERPINB2 (A004139), UCSD-Nature Molecule Pages, 2010. doi:. doi:10.1038/mp.a004139.01.
48. Bouchet C., Hacene K., Martin P.M., Becette V., Tubiana-Hulin M., Lasry S., Oglobine J., Spyratos F. Dissemination risk index based on plasminogen activator system components in primary breast cancer. J. Clin. Oncol. 1999, 17:3048-3057.
49. Foekens J.A., Peters H.A., Look M.P., Portengen H., Schmitt M., Kramer M.D., Brunner N., Janicke F., Meijer-van Gelder M.E., Henzen-Logmans S.C., van Putten W.L.J., Klijn J.G.M. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res. 2000, 60:636-643.
50. Deng G., Curriden S.A., Wang S., Rosenberg S., Loskutoff D.J. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?. J. Cell Biol. 1996, 134:1563-1571.